Literature DB >> 30302226

How can we better predict treatment outcomes in classical Hodgkin's lymphoma?

Claudio Agostinelli1.   

Abstract

Entities:  

Keywords:  Hodgkin; PET-2; biomarkers

Year:  2017        PMID： 30302226      PMCID： PMC6171983          DOI： 10.2217/ijh-2017-0010

Source DB:  PubMed          Journal:  Int J Hematol Oncol        ISSN： 2045-1393


× No keyword cloud information.
  17 in total

1.  The prognostic value of positron emission tomography performed after two courses (INTERIM-PET) of standard therapy on treatment outcome in early stage Hodgkin lymphoma: A multicentric study by the fondazione italiana linfomi (FIL).

Authors:  Luigi Rigacci; Benedetta Puccini; Pier Luigi Zinzani; Alberto Biggi; Antonio Castagnoli; Francesco Merli; Monica Balzarotti; Caterina Stelitano; Michele Spina; Umberto Vitolo; Vittorio Stefoni; Alessandro Levis; Manuel Gotti; Sancetta Rosaria; Stefani Piero Maria; Alberto Bosi; Andrea Gallamini
Journal:  Am J Hematol       Date:  2015-05-10       Impact factor: 10.047

2.  Long-term follow-up of survival in Hodgkin's lymphoma.

Authors:  George P Canellos; Donna Niedzwiecki; Jeffrey L Johnson
Journal:  N Engl J Med       Date:  2009-12-10       Impact factor: 91.245

3.  The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale.

Authors:  Andrea Gallamini; Sally F Barrington; Alberto Biggi; Stephane Chauvie; Lale Kostakoglu; Michele Gregianin; Michel Meignan; George N Mikhaeel; Annika Loft; Jan M Zaucha; John F Seymour; Michael S Hofman; Luigi Rigacci; Alessandro Pulsoni; Morton Coleman; Eldad J Dann; Livio Trentin; Olivier Casasnovas; Chiara Rusconi; Pauline Brice; Silvia Bolis; Simonetta Viviani; Flavia Salvi; Stefano Luminari; Martin Hutchings
Journal:  Haematologica       Date:  2014-03-21       Impact factor: 9.941

4.  ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned.

Authors:  Simonetta Viviani; Pier Luigi Zinzani; Alessandro Rambaldi; Ercole Brusamolino; Alessandro Levis; Valeria Bonfante; Umberto Vitolo; Alessandro Pulsoni; Anna Marina Liberati; Giorgina Specchia; Pinuccia Valagussa; Andrea Rossi; Francesco Zaja; Enrico M Pogliani; Patrizia Pregno; Manuel Gotti; Andrea Gallamini; Delia Rota Scalabrini; Gianni Bonadonna; Alessandro M Gianni
Journal:  N Engl J Med       Date:  2011-07-21       Impact factor: 91.245

5.  Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells.

Authors:  Tomás Alvaro; Marylène Lejeune; Ma Teresa Salvadó; Ramón Bosch; Juan F García; Joaquín Jaén; Alison H Banham; Giovanna Roncador; Carlos Montalbán; Miguel A Piris
Journal:  Clin Cancer Res       Date:  2005-02-15       Impact factor: 12.531

6.  International Prognostic Score in advanced-stage Hodgkin's lymphoma: altered utility in the modern era.

Authors:  Alden A Moccia; Jane Donaldson; Mukesh Chhanabhai; Paul J Hoskins; Richard J Klasa; Kerry J Savage; Tamara N Shenkier; Graham W Slack; Brian Skinnider; Randy D Gascoyne; Joseph M Connors; Laurie H Sehn
Journal:  J Clin Oncol       Date:  2012-08-06       Impact factor: 44.544

7.  Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial.

Authors:  King L Tan; David W Scott; Fangxin Hong; Brad S Kahl; Richard I Fisher; Nancy L Bartlett; Ranjana H Advani; Rena Buckstein; Lisa M Rimsza; Joseph M Connors; Christian Steidl; Leo I Gordon; Sandra J Horning; Randy D Gascoyne
Journal:  Blood       Date:  2012-09-04       Impact factor: 22.113

8.  Meta-analysis of the prognostic and clinical value of tumor-associated macrophages in adult classical Hodgkin lymphoma.

Authors:  Baoping Guo; Hong Cen; Xiaohong Tan; Qing Ke
Journal:  BMC Med       Date:  2016-10-17       Impact factor: 8.775

9.  The prognostic value of the myeloid-mediated immunosuppression marker Arginase-1 in classic Hodgkin lymphoma.

Authors:  Alessandra Romano; Nunziatina Laura Parrinello; Calogero Vetro; Daniele Tibullo; Cesarina Giallongo; Piera La Cava; Annalisa Chiarenza; Giovanna Motta; Anastasia L Caruso; Loredana Villari; Claudio Tripodo; Sebastiano Cosentino; Massimo Ippolito; Ugo Consoli; Andrea Gallamini; Stefano Pileri; Francesco Di Raimondo
Journal:  Oncotarget       Date:  2016-10-11

10.  PET-CT for staging and early response: results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study.

Authors:  Sally F Barrington; Amy A Kirkwood; Antonella Franceschetto; Michael J Fulham; Thomas H Roberts; Helén Almquist; Eva Brun; Karin Hjorthaug; Zaid N Viney; Lucy C Pike; Massimo Federico; Stefano Luminari; John Radford; Judith Trotman; Alexander Fosså; Leanne Berkahn; Daniel Molin; Francesco D'Amore; Donald A Sinclair; Paul Smith; Michael J O'Doherty; Lindsey Stevens; Peter W Johnson
Journal:  Blood       Date:  2016-01-08       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.